asset acquisition

Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.

Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.

A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them.

Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.

Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.

Population Genetics was formed to commercialize the IP portfolio of Sydney Brenner focused on high sensitivity and high specificity NGS detection.

The purchase provides Thermo Fisher with access to the $40 billion pharmaceutical contract development and manufacturing market.

Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.

The clinical genetics and genomics testing firm said the funding will help as it seeks to consolidate its presence in international markets.

The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.

Pages

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.